ClinicalTrials.gg
CompletedNCT03303989RECIPEUpdated Mar 16, 2022Results posted

REduCing Immunogenicity to PegloticasE (RECIPE) Study

A Phase 2 interventional study of Pegloticase 8 MG/ML [Krystexxa] and MMF in Gout Chronic, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by University of Alabama at Birmingham · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
102nd of 149
35 · median 74
Started
2018
with 4 others
Phase 2
45 of 164
2 open now
Registered
90th of 164
by date
Lead sponsor
6 of 164
University of Alabama at Birmingham

Among the 164 studies in Gout with a site in United States, this one is the 102nd largest by enrollment of the 149 interventional ones that give a count, is one of 5 that started in 2018, is one of 45 in phase 2, and was the 90th registered.

Gout

345 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

Pegloticase treatment for chronic refractory gout is limited by immunogenicity. The investigators propose the REduCing Immunogenicity to PegloticasE (RECIPE) trial to begin to investigate the question of whether a short course of immune modulating therapy with mycophenolate mofetil can significantly and safely attenuate immunogenicity to pegloticase and ensure patients afflicted with chronic refractory gout have better treatment outcomes and improved quality of life.

Read the detailed description

Pegloticase is highly efficacious therapy for chronic refractory gout patients (n = > 400K in the US alone). It decreases serum urate (sUA) levels to often undetectable levels and reduces tophi burden. However, its long-term real world effectiveness is severely limited due to its immunogenicity caused by anti-pegloticase antibody formation. REducing Immunogenicity to PEgloticase (RECIPE) is a Phase II, double-blind, placebo controlled, proof-of-concept trial in 32 subjects initiating pegloticase for treatment of chronic refractory gout. RECIPE will investigate the preliminary efficacy and safety of using immune modulating therapy with mycophenolate mofetil (MMF) to prevent immunogenicity conferred by pegloticase. Subjects will be randomized 3:1 to receive MMF vs. placebo in addition to everyone receiving pegloticase. The co-primary aims of the RECIPE trial are to 1) determine if a 12 week course of immune modulating therapy with daily MMF can safely and significantly attenuate immunogenicity to pegloticase as determined by the proportion of participants achieving and maintaining an sUA less than or equal to 6 mg/dL through 12 weeks, compared to concurrent controls, and 2) to assess the incidence and types of adverse events and infusion reaction. After 12 weeks of co-administration, all participants will continue on pegloticase for an additional 12 weeks without combination MMF immune modulating therapy to evaluate the longer term benefits (durability) and safety of this approach. The secondary aims are to: 1) Determine the 6 month durability of immune modulation after discontinuation of the short course of MMF by: a) assessing the absolute change in sUA from baseline to Week 24, and Week 12 to Week 24 and b) determining the proportion of participants with sUA ≤ 6 mg/dL through 24 weeks, and Week 12 to Week 24; 2) Identify and characterize the pegloticase immune response by immunoglobulin isotypes (IgG and IgM), specificities, and antibody titer; and 3) Examine patient reported outcomes (PROs) using the NIH supported Patient Reported Outcomes Measurement Information System (PROMIS) and Gout Impact Scale (GIS) instruments. The University of Alabama at Birmingham (UAB) and the University of Michigan (UM), two large academic gout and immunology research centers, which in aggregate see nearly 10,000 gout patients annually, will serve as the two lead study sites and are very well-positioned to address the clinical and immunologic questions posed.

03

Conditions studied

  • Gout Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women > 18 years of age
  • Diagnosed with chronic gout*

    • Defined as: Persons whose signs and symptoms are inadequately controlled with urate lowering therapy (e.g. xanthine oxidase inhibitors or uricosuric agents) at a medically appropriate dose or for whom these drugs are .

Exclusion criteria

Exclusion Criteria:

  • Any serious acute bacterial infection (2 weeks prior to Visit 1), unless treated and completely resolved with antibiotics
  • Severe chronic or recurrent bacterial infections (such as recurrent pneumonia, chronic bronchiectasis)
  • Current condition, including current or chronic treatment with immunosuppressive agents
  • Subjects at risk for tuberculosis. Specifically, subjects with: i) current clinical, radiographic or laboratory evidence of active or latent TB; ii) a history of active TB within the last 3 years even if it was treated; iii) a history of active TB greater than 3 years ago unless there is documentation that the prior anti-TB treatment was appropriate in duration and type
  • Known surface antigen-positive or Hepatitis B DNA positive subjects
  • Known RNA-positive subjects
  • (HIV) infection
  • G6PD deficiency (tested at Screening Visit 1)
  • Severe chronic renal impairment ( [GFR] \<25 mL/min/1.73 m2) or currently on dialysis
  • Subjects having any transplant surgery requiring maintenance immunosuppressive therapy
  • Non-compensated congestive heart failure, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or hospitalization for congestive heart failure within 3 months of screening or uncontrolled blood pressure (>160/100 mm Hg) at baseline (Screening Visit 1 and Week 0/Baseline visits)
  • Participants who are pregnant, planning to become pregnant, breastfeeding, or not on an effective form of (defined in Study Protocol section 7.1)
  • Prior treatment with pegloticase, another recombinant uricase, or concomitant therapy with a polyethylene glycol (PEG)-conjugated drug
  • Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product
  • Subjects in whom MMF treatment is or considered inappropriate
  • Recipient of an drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
  • Current liver disease as determined by ALT or aspartate transaminase (AST) levels >3 times
  • Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer
  • History of within 5 years other than skin cancer or in situ carcinoma of cervix
  • Uncontrolled hyperglycemia with a plasma glucose value >240 mg/dL at screening
  • Diagnosed osteomyelitis
  • Individuals with hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) deficiency such as Lesch-Nyhan and Kelley-Seegmiller syndrome
  • Not good candidate for the study based on opinion of the Investigator (e.g., cognitive impairment) that might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements, or to complete the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    pegloticase + MMF

    Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.

    Drug: Pegloticase 8 MG/ML [Krystexxa] · Drug: MMF

  • Placebo comparator
    pegloticase + placebo

    Participants randomized to this arm will receive pegloticase + placebo

    Drug: Placebo · Drug: Pegloticase 8 MG/ML [Krystexxa]

Interventions

  • DrugPegloticase 8 MG/ML [Krystexxa]

    Drug page: Pegloticase

    Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.

    Also known as: Krystexxa

  • DrugMMF

    Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.

    Also known as: Cell Cept

  • DrugPlacebo

    Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.

  • DrugPegloticase 8 MG/ML [Krystexxa]

    Drug page: Pegloticase

    Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.

    Also known as: Krystexxa

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks

    Proportion of participants achieving and maintaining an sUA ≤ to 6 mg/dL through 12 weeks, compared to concurrent controls.

    Time frame: 12 weeks

07

Results

Posted Nov 10, 2021

Participant flow

Participant flow — Overall Study
MilestonePegloticase + MMFPegloticase + Placebo
Started2411
Completed2210
Not completed21

Outcome measures

PrimaryProportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks

Proportion of participants achieving and maintaining an sUA ≤ to 6 mg/dL through 12 weeks, compared to concurrent controls.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Proportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks
ParticipantsPegloticase + MMFPegloticase + Placebo
Yes194
No36
Statistical analysis
  • Pegloticase + MMF vs Pegloticase + Placebo · Fisher Exact · p = <0.01

Adverse events

Collected over 36 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegloticase + MMF0/22 (0%)2/22 (9.1%)15/22 (68.2%)
Pegloticase + Placebo0/10 (0%)1/10 (10%)7/10 (70%)
Most frequent serious events
Most frequent serious events
EventPegloticase + MMFPegloticase + Placebo
Infusion ReactionSkin and subcutaneous tissue disorders0/221/10
Motor Vehicle CrashInjury, poisoning and procedural complications1/220/10
Chest PainCardiac disorders1/220/10
Abdominal PainGastrointestinal disorders1/220/10
Most frequent other events
Most frequent other events
EventPegloticase + MMFPegloticase + Placebo
Other (Lab abnormality, anxiety, neurological, and oral pain)General disorders9/225/10
Musculoskeletal (arthralgia, myalgia, low back pain, orthopedic trauma, bursitis tendonitis)Musculoskeletal and connective tissue disorders9/221/10
GastrointestinalGastrointestinal disorders4/221/10
CardiaCardiac disorders2/221/10
SkinSkin and subcutaneous tissue disorders2/221/10
InfectionsInfections and infestations2/220/10

Baseline characteristics

35 participants were randomized. Three participants withdrew after randomization, but prior to first pegloticase infusion. Baseline characteristics are of the 32 participants (22 in MMF+Peg, 10 in PBO+Peg)

Age, Continuous
Age, Continuous(years)Pegloticase + MMFPegloticase + PlaceboTotal
Mean55 ± 9.455.5 ± 10.755.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase + MMFPegloticase + PlaceboTotal
Female314
Male19928
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase + MMFPegloticase + PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino221032
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegloticase + MMFPegloticase + PlaceboTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American505
White151025
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Pegloticase + MMFPegloticase + PlaceboTotal
United States221032
American College of Rheumatology / European League Against Rheumatism Flare Criteria Score
American College of Rheumatology / European League Against Rheumatism Flare Criteria Score(Score on a scale)Pegloticase + MMFPegloticase + PlaceboTotal
Mean13.5 ± 2.813.8 ± 2.713.5 ± 2.6
Gout Flare History (flare within the last year)
Gout Flare History (flare within the last year)(Participants)Pegloticase + MMFPegloticase + PlaceboTotal
Yes15520
No7512
Duration of Gout
Duration of Gout(years)Pegloticase + MMFPegloticase + PlaceboTotal
Mean13.3 ± 9.813.4 ± 7.413.4 ± 9.0

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
09

References and documents

Publications

  • Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, Biggers S, Rahman AKMF, Kuo HC, Feese M, Kivitz A, King C, Shergy W, Kent J, Peloso PM, Danila MI, Saag KG. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021 Aug;73(8):1523-1532. doi: 10.1002/art.41731. Epub 2021 May 19. PubMed 33750034 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2020, 22 months.

Results were first posted in Nov 2021, 1 year 6 months after primary completion.

Of 30 phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 6, 2017
StartActual
Jun 14, 2018
Primary completionActual
Apr 27, 2020
CompletionActual
Mar 31, 2021
Results first posted
Nov 10, 2021
Last update
Mar 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03303989
Responsible party
Kenneth Saag, MD, MSc (Professor of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 6, 2017
Start date
Jun 14, 2018
Primary completion
Apr 27, 2020
Completion
Mar 31, 2021
Results posted
Nov 10, 2021
Last update
Mar 16, 2022

Study contacts

Kenneth G Saag, MD
principal investigator · Professor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion